Reduce the number of smokers by using heated tobacco products as an aid to stopping smoking

If you're looking for an alternative to smoking that doesn't include burning or producing smoke, heated tobacco products, or HTPs, are what you're looking for. They differ from e-cigarettes in that they don't use electronic liquids but rather heat tobacco leaves or sheets. The manufacturers of HTPs claim that their products produce less dangerous compounds than regular cigarettes. Whether or not HTPs are effective for this purpose and whether or not they pose a major danger to patients, some patients have reported being able to completely stop smoking cigarettes after using HTPs. Policymakers must also have a thorough grasp of the impact of HTPs on the health of individuals and the number of people who smoke cigarettes in order to regulate them appropriately. Read the iqos review below.

Objectives

For this research, the goal is to examine the effectiveness and safety of HTPs for smoking cessation, as well as the impact of HTPs on smoking prevalence.

Techniques for looking for

The Cochrane Tobacco Addiction Group's Specialised Register, Central, and six additional databases were evaluated for pertinent material up to January 2021 in addition to reference checking and establishing contact with relevant organisations.

The selection criteria

RCTs in which cigarette smokers had been randomly assigned to stop using tobacco products or a control condition were also included. HTP users served as the subjects for these research. It was decided that the following outcomes were all valid: cessation of smoking, incidence of adverse events, and assessment of selected biomarkers RCTs that were conducted in a clinical or ambulatory setting were eligible for inclusion in the safety assessment. Randomly allocated participants were asked to either use HTPs exclusively or smoke cigarettes or abstain from any tobacco usage at all. As an indirect indicator of the impact of heated tobacco on smoking prevalence or cigarette sales, time-series studies were also eligible for inclusion. In order for the study to be approved, this had to be done.

The collection and analysis of data

We followed the typical Cochrane screening and data gathering procedures. Among the most important outcomes we looked at were changes in smoking prevalence or cigarette sales, adverse events, the incidence of major adverse events, and abstinence from smoking at the point in time with the longest follow-up.